Presentation previews · Artwork labels are not verified filling specifications. Purchasing is not available.

AEVIA MED / VIALS
AOD-9604
Growth-hormone-fragment analogue investigated in lipid-metabolism models.
FOR LABORATORY RESEARCH USE ONLY
NOT FOR HUMAN OR ANIMAL USE.
Do not inject, ingest or otherwise administer to humans or animals.
Research-use policy →Price
Price to confirm
Presentation status
Supplied visual concept. The printed amount is an artwork reference, not confirmation of AEVIA filling, formulation, physical state or use. It is not an application dose.
Research-only intended use
This product is intended solely for laboratory research conducted by appropriately trained personnel in suitable laboratory facilities. It must not be used in or on humans or animals, including by injection, ingestion or topical application.
It is not supplied for clinical, diagnostic, therapeutic, veterinary, cosmetic, food or supplement use. References to published studies describe research context only; they are not instructions or recommendations to use this product in people or animals.
The quantity stated on the container is the total supplied content, not an administration dose. Consult the applicable product documentation and safety data before laboratory handling. A product or batch record match does not establish suitability for human or animal use.
Research-use policy →Compound identity and research context · Separate from the exact product specification
What it is
AOD-9604 is a synthetic analogue based on a C-terminal domain of growth hormone.
Biological target / research area
Lipid metabolism and fat oxidation have been investigated in animal experiments; it is not simply equivalent to intact growth hormone.
What the research examined
Evidence context: preclinical with safety gap
The selected primary studies used obese rats and mice. A receptor experiment distinguished its activity from intact growth hormone.
Evidence limitations
Animal findings do not establish clinically effective human fat loss. The FDA has also identified important safety-data gaps for compounded AOD-9604.
AOD-9604 · 5 mg: this printed quantity identifies the artwork presentation. It is not a verified filling specification or an application dose.
Selected references
- Metabolic actions of AOD9604 in obese Zucker rats (2001) ↗ · Reviewed 14/10/2026
- hGH and AOD9604 in fat oxidation and receptor experiments (2001) ↗ · Reviewed 14/10/2026
- FDA: bulk substances that may present significant safety risks ↗ · Reviewed 14/10/2026
Composition & specification
Verified product specifications and release documentation are pending. No dosing, preparation or administration instructions are provided.
Storage, safety & batch information
Product-specific storage, expiry and safety documentation must be confirmed for the exact released presentation. Use the exact-presentation batch reference lookup in the product guide. A record match does not authenticate physical contents.